HAPVIDA (HAPV3) Main Indicators
Basic Data - HAPV3
| Company | HAPVIDA |
| Corporate Name | HAPVIDA PARTICIPACOES E INVESTIMENTOS SA |
| Registration Status | ATIVO |
| Issuer Status | FASE OPERACIONAL |
| Listing Segment | Novo Mercado |
| Activity | Participação. como sócia ou acionista. em outras empresas. predominantemente de assistência médica. bem como a realização de investimentos diretos e a exploração de atividades de prestação de serviços |
| Share | HAPV3 |
| Quote Date | 11/08/2024 |
| Share Type | ON |
| Last Closing | R$ 3.19 |
| Quotation Factor | 1 Share |
| Financial Volume | R$ 308.03 M |
| Last Statement | ITR - 06/30/2024 |
| Sector | Saúde |
| Subsector | Serv.Méd.Hospit..Análises e Diagnósticos |
| Segment | Serv.Méd.Hospit..Análises e Diagnósticos |
| Participation Indexes | IBOVESPA, IBRA, IBRX, IBRX50, ICON, IGC, IGCT, IGNM, ITAG, IVBX, MLCX |
| Updated 11/09/2024 | |
Relative Prices - HAPV3
| Price/Earnings | -43.82 |
| Price/SBV | 0.49 |
| Price/Net Sales | 0.88 |
| Price/CFO | 8.74 |
| Price/FCF | 9.10 |
| Price/Total Assets | 0.32 |
| Price/EBIT | 20.47 |
| Price/Working Capital | 8.50 |
| Price/NCAV | -1.06 |
| EV/EBIT | 30.12 |
| EV/EBITDA | 21.46 |
| EV/Net Sales | 1.29 |
| EV/CFO | 12.86 |
| EV/FCF | 13.39 |
| EV/Total Assets | 0.48 |
| Company Market Cap | R$ 24.05 B |
| Enterprise Value | R$ 35.39 B |
| Current Financial Statement Date | 06/30/2024 |
| Current Share Price | R$ 3.19 |
| Share Price Date | 11/08/2024 |
| Dividend Yield | 0.00% |
| Updated 11/09/2024 | |
Income Statement - HAPV3
| Net Revenue | R$ 27.33 B |
| Gross Result | R$ 3.11 B |
| EBIT | R$ 1.17 B |
| Depreciation and Amortization | - R$ 473.92 M |
| EBITDA | R$ 1.65 B |
| Net Profit | - R$ 548.82 M |
| Net Profit/Share | - R$ 0.07 |
| Updated 08/19/2024 | |
| Net Revenue | R$ 437.10 M |
| Gross Result | R$ 149.90 M |
| EBIT | - R$ 313.41 M |
| Depreciation and Amortization | - R$ 112.70 M |
| EBITDA | - R$ 200.71 M |
| Net Profit | - R$ 381.35 M |
| Profit/Share | - R$ 0.05 |
| Updated 08/19/2024 | |
Price and Volume Behavior - HAPV3
| Lowest Price 52 weeks | R$ 3.19 |
| Highest Price 52 weeks | R$ 4.71 |
| Variation 2024 | -25.64% |
| Variation 1 year | -25.99% |
| Variation 2 years(total) | -57.92% |
| Variation 2 years(yearly) | -35.09% |
| Variation 3 years(total) | -74.99% |
| Variation 3 years(yearly) | -36.97% |
| Variation 4 years(total) | -77.59% |
| Variation 4 years(yearly) | -31.15% |
| Variation 5 years(total) | -71.09% |
| Variation 5 years(yearly) | -21.96% |
| Average Daily Volume (3 months) | R$ 254.49 M |
| Updated 11/09/2024 | |
Returns and Margins - HAPV3
| Return on Initial Tangible Capital | 4.62% |
| Return on Initial Invested Capital | 1.28% |
| Pre-Tax Return on Initial Tangible Capital | 7.00% |
| Pre-Tax Return on Initial Invested Capital | 1.95% |
| Return on Initial Shareholder´s Equity | -1.11% |
| Return on Initial Asset | -0.73% |
| Gross Margin | 11.37% |
| Net Margin | -2.01% |
| EBIT Margin | 4.30% |
| EBITDA Margin | 6.03% |
| Initial Asset Turnover | 0.36 |
| Financial Leverage | 1.52 |
| Liabilities/Net Worth | 0.52 |
| Net Debt/EBITDA | 6.88 |
| Updated 08/19/2024 | |
Balance Sheet - HAPV3
| Cash and Cash Equivalents | R$ 419.68 M |
| Total Assets | R$ 74.20 B |
| Short-Term Debt | R$ 1.27 B |
| Long-Term Debt | R$ 10.49 B |
| Gross Debt | R$ 11.76 B |
| Net Debt | R$ 11.34 B |
| Shareholder´s Equity | R$ 48.75 B |
| Share Book Value | R$ 6.47 |
| Common Shares | 7,539,463,263 |
| Preferred Shares | 0 |
| Total | 7,539,463,263 |
| Common Shares in Treasury | 45,215,560 |
| Preferred Shares in Treasury | 0 |
| Total in Treasury | 45,215,560 |
| Common Shares (Except Treasury) | 7,494,247,703 |
| Preferred Shares (Except Treasury) | 0 |
| Total (Except Treasury) | 7,494,247,703 |
| Updated 08/19/2024 | |
Cash Flow - HAPV3
| Operating Cash Flow | R$ 2.75 B |
| Cash Flow from Investments | - R$ 721.58 M |
| Financing Cash Flow | - R$ 2.15 B |
| Increase (Reduction) in Cash and Equivalents | - R$ 114.98 M |
| Updated 08/19/2024 | |
| Operating Cash Flow | R$ 516.11 M |
| Cash Flow from Investments | - R$ 964.22 M |
| Financing Cash Flow | R$ 41.21 M |
| Increase (Reduction) in Cash and Equivalents | - R$ 406.90 M |
| Updated 08/19/2024 | |
Experimental - HAPV3
| CAPEX 3 months | - R$ 46.39 M |
| Free Cash Flow 3 months | R$ 469.72 M |
| CAPEX 12 months | - R$ 109.70 M |
| Free Cash Flow 12 months | R$ 2.64 B |
| Updated 08/19/2024 | |